Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT193 in Hidradenitis Suppurativa
NCT04989517Phase 1Completed
- Sponsor
- Azora Therapeutics
- Start
- Nov 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing AT193 with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events at 10 weeks. Started Nov 2021; status: completed.
02
Drugs
AT-193
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04989517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989517.